Annual Reports

 
Quarterly Reports

 
8-K

  • 8-K (Jul 29, 2014)
  • 8-K (Jul 17, 2014)
  • 8-K (Jun 23, 2014)
  • 8-K (Jun 13, 2014)
  • 8-K (May 13, 2014)
  • 8-K (Mar 31, 2014)

 
Other

ANTHERA PHARMACEUTICALS 8-K 2012

Documents found in this filing:

  1. 8-K
  2. Ex-99.1
  3. Ex-99.1

 

 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): March 1, 2012

 

ANTHERA PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-34637

 

20-1852016

(State or other jurisdiction of
incorporation)

 

(Commission File Number)

 

(I.R.S. Employer
Identification No.)

 

25801 Industrial Boulevard, Suite B, Hayward, California

 

94545

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (510) 856-5600

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 5.02

Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.

 

(d)           On March 1, 2012, the Board of Directors (the “Board”) of Anthera Pharmaceuticals, Inc. (the “Company”), on the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Bogdan Dziurzynski to serve on the Board as a Class II director.

 

Bogdan Dziurzynski, D.P.A. has been a consultant in strategic regulatory management to the biotechnology industry since 2001.   Dr. Dziurzynski serves on the Board of the Biologics Consulting Group and the Board of Directors of Dendreon Corporation, a biotechnology company.  Dr. Dziurzynski is a fellow, past chairman of the board and a past president of the Regulatory Affairs Professional Society. He also serves as an advisory board member of Integrated Biotherapeutics, Inc. From 1994 to 2001, Dr. Dziurzynski was the Senior Vice President of Regulatory Affairs and Quality Assurance for MedImmune, Inc., a biotechnology company. From 1988 to 1994, Dr. Dziurzynski was Vice President of Regulatory Affairs and Quality Assurance for Immunex Corporation, a biotechnology company. Dr. Dziurzynski has a B.A. in Psychology from Rutgers University, an M.B.A. from Seattle University and a Doctorate in Public Administration from the University of Southern California.

 

A copy of the press release announcing Dr. Dziurzynski appointment is filed herewith as Exhibit 99.1

 

(e)           In addition, on March 1, 2012, effective April 1, 2012, the Company’s Board, upon the recommendation of the Compensation Committee of the Board, approved annual base salary adjustments for certain of the Company’s employees, including certain of the Company’s named executive officers as part of its annual review of compensation.  The adjusted salaries for such named executive officers are as follows:

 

Named Executive Officer

 

2011 Annual Base Salary

 

Annual Base Salary
Effective April 1, 2012

 

Paul F. Truex, President and Chief Executive Officer

 

$

500,000

 

$

515,000

 

Christopher P. Lowe, Vice President of Administration and Chief Business Officer

 

$

340,000

 

$

350,000

 

Colin Hislop, M.D., Senior Vice President and Chief Medical Officer

 

$

340,000

 

$

350,000

 

Debra Odink, Ph.D., Senior Vice President and Chief Technology Officer

 

$

270,000

 

$

340,000

 

Georgina Kilfoil, Senior Vice President, Product Development and Project Management

 

$

250,000

 

$

265,000

 

 

Item 9.01

Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.

 

Description

 

 

 

99.1

 

Press Release, dated March 5, 2012

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: March 5, 2012

Anthera Pharmaceuticals, Inc.

 

 

 

 

 

By:

/s/ Christopher P. Lowe

 

 

Christopher P. Lowe

 

 

Chief Financial Officer

 

3



 

Exhibit Index

 

Exhibit No.

 

Description

 

 

 

99.1

 

Press Release, dated March 5, 2012

 

4


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki